Skip to content
MarketScale
‹ Back to IndustriesSciences

THE OUTLOOK FOR ENZYME SUPPLEMENTS IS STRONGER THAN EVER

According to the market research firm Credence Research, Inc., the digestive enzyme supplements market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.9% over the coming years, reaching about $1.6 billion by 2025.[1] This growth is being driven by conditions like lactose intolerance, as well as a growing awareness and concern over those…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Promoted Content
Share
THE OUTLOOK FOR ENZYME SUPPLEMENTS IS STRONGER THAN EVER

Key takeaways

01

According to the market research firm Credence Research, Inc., the digestive enzyme supplements market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.9% over the coming years, reaching about $1.6 billion by 2025.[1] This growth is being driven by conditions like lactose intolerance, as well as a growing awareness and concern over those…

According to the market research firm Credence Research, Inc., the digestive enzyme supplements market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.9% over the coming years, reaching about $1.6 billion by 2025.[1] This growth is being driven by conditions like lactose intolerance, as well as a growing awareness and concern over those wanting to improve their digestive health by using probiotics and prebiotics. Let’s take a look at the outlook of the enzyme supplement market.

The World Regions Driving the Growth of Enzyme Supplements

In 2016, the North American region was the world leader in revenue share for enzyme supplements. This can be attributed to consumers with gastrointestinal issues, an increased emphasis on maintaining a healthy lifestyle, and the growing access to dietary supplements from manufacturers and suppliers. The most rapidly growing market segment, however, was the Asia-Pacific region, which is expected to grow by over 7.5 % by 2024.[2] This is due to factors such as a large aging population and a dietary preference for oily and spicy food.

Enzyme Supplements Aid Digestion for a Large Segment of the Population

The human body produces 22 different types of enzymes.[3] Digestive enzymes are beneficial in easing the stress on the stomach, gallbladder, liver, small intestine, and pancreas when processing starches, fats, and proteins. Unfortunately, from time to time, the body may have shortages of certain digestive enzymes due to a number of issues. One such factor is lactase deficiency, commonly known as lactose intolerance, a condition that affects approximately 70% of the world’s population.[4] Gluten sensitivity is becoming more prevalent as well. Finally, the natural aging process itself greatly reduces the body’s ability to produce digestive enzymes, lowering digestive activity by as much as 50%.[5]

Enzyme Supplements Offer a Number of Important Benefits

Even those without a shortage of digestive enzymes realize a number of important benefits in taking enzyme supplements. Many consumers may experience gastrointestinal discomfort due to consuming fast food, sugars, and artificial preservatives and sweeteners that can negatively affect the gut flora that comprise the microbiome. In addition, there is a rising demand for natural sports nutrition products among athletes, fitness enthusiasts, and even casual exercisers looking to improve their performance and overall sense of well-being. Finally, an aging world population is looking for ways to stay healthy and vibrant during their golden years.

Deerland Enzymes & Probiotics is Positioned to Address this Growing Need

There can be no doubt that the outlook for enzyme supplements will be very strong in the years ahead. At Deerland, we work closely with our customers at the early concept phase of product development to ensure we are helping them to deliver the benefits consumers desire and that meet their specific needs. Our product development team creates a wide range of specialized supplement formulas that include enzymes, probiotics and prebiotics.

To learn more, please visit http://www.deerlandenzymes.com/products/ today.

[1] https://www.credenceresearch.com/press/global-digestive-enzymes-supplements-market

[2] https://www.gminsights.com/industry-analysis/enzymes-market

[3] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

[4] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

[5] https://www.credenceresearch.com/report/digestive-enzymes-supplements-market

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512